[Code of Federal Regulations]

[Title 40, Volume 31]

[Revised as of July 1, 2006]

From the U.S. Government Printing Office via GPO Access

[CITE: 40CFR799.5075]



[Page 272-275]

 

                   TITLE 40--PROTECTION OF ENVIRONMENT

 

         CHAPTER I--ENVIRONMENTAL PROTECTION AGENCY (CONTINUED)

 

PART 799_IDENTIFICATION OF SPECIFIC CHEMICAL SUBSTANCE AND MIXTURE 

TESTING REQUIREMENTS--Table of Contents

 

                   Subpart D_Multichemical Test Rules

 

Sec.  799.5075  Drinking water contaminants subject to testing.



    (a) Identification of test substance. (1) 1,1,2,2-tetrachloroethane 

(CAS No. 79-34-5), and 1,3,5-trimethylbenzene (CAS No. 108-67-8) shall 

be tested as appropriate in accordance with this section.

    (2) A test substance of at least 99 percent purity shall be used for 

Chloroethane, 1,1-dichloroethane, and 1,3,5-trimethylbenzene. A test 

substance of at least 98 percent purity shall be used for 1,1,2,2-

tetrachloroethane.

    (b) Persons required to submit study plans, conduct tests, and 

submit data. All persons who manufacture (including import and by-

product manufacture) or process, or who intend to manufacture or 

process, the substances listed in paragraph (a) of this section after 

the effective date of this section to the end of the reimbursement 

period shall submit letters of intent to test, submit study plans, 

conduct tests, and submit data, or submit exemption applications as 

specified in this section, subpart A of this part, and parts 790 and 792 

of this chapter for single-phase rulemaking, for the substances they 

manufacture subject to exclusions contained in Sec.  790.42(a)(2), 

(a)(4) and (a)(5). These sections provide that processors, persons who 

manufacture less than 500 kg (1,100 lbs) annually, or persons who 

manufacture small quantities of the chemical solely for research and 

development as defined in Sec.  790.42(a)(5) shall not be required to 

submit study plans, conduct tests and submit data, or submit exemption 

applications as specified in this section unless directed to do so in a 

subsequent notice as set forth in Sec.  790.48(b).

    (c) Health effects testing--(1) Subacute toxicity--(i) Required 

testing. (A) An oral 14-day repeated dose toxicity test shall be 

conducted with 1,1,2,2-tetrachloroethane, and 1,3,5-trimethylbenzene in 

accordance with Sec.  798.2650 of this chapter except for the provisions 

in Sec.  798.2650 (a), (b)(1), (c), (e)(3), (e)(4)(i), (e)(5), (e)(6), 

(e)(7)(i), (e)(7)(iv), (e)(7)(v), (e)(8)(vii), (e)(9)(i)(A), 

(e)(9)(i)(B), (e)(11)(v), and (f)(2)(i). Each substance shall be tested 

in one mammalian species, preferably a rodent, but a non-rodent may be 

used. The species and strain of animals used in this test should be the 

same as those used in the 90-day subchronic test required in paragraph 

(c)(2)(i) of this section. The tests shall be performed using drinking 

water. However, if, due to poor stability or palatability, a drinking 

water test is not feasible for a given substance, that substance shall 

be administered either by oral gavage, in the diet, or in capsules.

    (B) For the purpose of this section, the following provisions also 

apply:

    (1) Purpose. To assess and evaluate the toxic characteristics of a 

substance, the determination of subacute toxicity should be carried out 

after initial information on toxicity has been obtained by acute 

testing. The 14-day repeated dose oral study provides information on the 

health hazard likely to arise from repeated short-term exposure by the 

oral route over a very limited period of time. It has been designed to 

permit the determination of the no-observed-adverse-effect level



[[Page 273]]



and toxic effects associated with continuous or repeated exposure to a 

test substance for 14 days and to evaluate reversibility, persistence, 

and delayed occurrence of toxic effects during a 14-day follow-up 

recovery period. The test is not capable of determining those effects 

that have a long latency period for development (e.g., carcinogenicity 

and life shortening). It will provide information on target organs and 

the possibility of accumulation, and can be used in selecting dose 

levels for subchronic studies and for establishing safety criteria for 

short-term human exposure.

    (2) Definitions. Subacute oral toxicity is the manifestation of 

adverse effect(s) occurring as a result of the repeated daily exposure 

of experimental animals to a substance by the oral route for 14 days.

    (3) Principle of the test method. The test substance is administered 

orally in graduated daily doses to several groups of experimental 

animals, one dose level per group, for a period of 14 days. During the 

period of administration the animals are observed daily to detect signs 

of toxicity. Animals which die during the period of administration are 

necropsied. At the conclusion of the test, all animals, except the 

satellite group, are necropsied and histopathological examinations are 

carried out. The satellite group is necropsied after the 14-day recovery 

period.

    (4) Satellite group (Rodent only). A satellite group of 20 animals 

(10 animals per sex) shall be treated with the high dose level for 14 

days and observed for reversibility, persistence, and delayed occurrence 

of toxic effects for a post-treatment recovery period of at least 14 

days.

    (5) Dose levels and dose selection. In subacute toxicity tests, it 

is desirable to have a dose response relationship as well as a NOAEL. 

Therefore, at least 3 dose levels with a control and, where appropriate, 

a vehicle control (corresponding to the concentration of vehicle at the 

highest exposure level) shall be used. Doses shall be spaced 

appropriately to produce test groups with a range of toxic effects. The 

data should be sufficient to produce a dose-response curve.

    (6) Exposure conditions. The animals are dosed with the test 

substance every day for 14 days.

    (7) Observation period. All animals shall be observed daily during 

the 14-day exposure period.

    (8) Observation period of satellite group. Animals in the satellite 

group scheduled for follow-up observations shall be kept for at least 14 

days further without treatment to detect recovery from, or persistence 

of, and delayed onset of toxic effects and shall be observed daily.

    (9) Administration of test substance. For substances of low 

toxicity, it is important to ensure that when administered in the 

drinking water, by gavage, in the diet, or in capsules, the quantities 

of the test substance involved do not interfere with normal nutrition. 

When the test substance is administered in the diet, either a constant 

dietary concentration (ppm) or a constant dose level in terms of the 

animals' body weight shall be used; the alternative used shall be 

specified in the final test report.

    (10) Time of administration of test substance. For a substance 

administered by gavage or capsule, the dose shall be given at 

approximately the same time each day, and adjusted on day 7 to maintain 

a constant dose level in terms of animal body weight.

    (11) Observation of animals. At the end of the 14-day exposure 

period, all survivors, except those in the satellite group, shall be 

necropsied. All survivors in the satellite group shall be necropsied 

after a recovery period of at least 14 days.

    (12) Hematology determinations. Certain hematology determinations 

shall be carried out at least two times during the test period: Just 

prior to initiation of dosing if adequate historical baseline data are 

not available (baseline data) and just prior to terminal sacrifice at 

the end of the test period. Hematology determinations which are 

appropriate to all studies are: Hematocrit, hemoglobin concentration, 

erythrocyte count, total and differential leukocyte count, and a measure 

of clotting potential such as clotting time, prothrombin time, 

thromboplastin time, or platelet count.



[[Page 274]]



    (13) Clinical biochemical determinations. Certain clinical 

biochemistry determinations on blood should be carried out at least two 

times: Just prior to initiation of dosing (if adequate historical 

baseline data are not available) and just prior to terminal sacrifice at 

the end of the test period. Test areas which are considered appropriate 

to all studies are: Electrolyte balance, carbohydrate metabolism, and 

liver and kidney function. The selection of specific tests will be 

influenced by observations on the mode of action of the substance. 

Suggested determinations are: Calcium, phosphorus, chloride, sodium, 

potassium, fasting glucose (with the period of fasting appropriate to 

the species), serum alanine aminotransferase, serum aspartate 

aminotransferase, gamma glutamyl transpeptidase, urea nitrogen, albumin, 

blood creatinine, and total serum protein measurements. Other 

determinations which may be necessary for an adequate toxicological 

evaluation include: analyses of lipids, hormones, acid/base balance, 

methemoglobin, and cholinesterase activity. Additional clinical 

biochemistry may be employed, where necessary, to extend the 

investigation of observed effects.

    (14) Histopathology. Histopathology of the lungs of all animals 

shall be performed. Special attention to examination of the lungs of 

rodents shall be made for evidence of infection since this provides a 

convenient assessment of the state of health of the animals.

    (15) Evaluation of the study results. The findings of a subacute 

oral toxicity study should be evaluated in conjunction with the findings 

of preceding studies and considered in terms of the toxic effects and 

the necropsy and histopathological findings. The evaluation will include 

the relationship between the dose of the test substance and the presence 

or absence, the incidence and severity, of abnormalities, including 

behavioral and clinical abnormalities, gross lesions, identified target 

organs, body weight changes, effects on mortality and any other general 

or specific toxic effects. A properly conducted subacute test should 

provide a satisfactory estimation of a NOAEL.

    (ii) Reporting requirements. (A) Each subacute test shall be 

completed and the final report submitted to EPA within 12 months of the 

date specified in paragraph (d)(1) of this section, except for 1,1,2,2-

tetrachloroethane. The subacute testing for 1,1,2,2-tetrachloroethane. 

The subacute testing for 1,1,2,2-tetrachloroethane shall be completed 

and the final report submitted to EPA by February 15, 1996.

    (B) Except for 1,3,5-trimethylbenzene, a progress report shall be 

submitted to EPA for each test beginning 6 months after the date 

specified in paragraph (d)(1) of this section and at 6-month intervals 

thereafter until the final report is submitted to EPA . The progress 

report for 1,3,5-trimethylbenzene shall be submitted to EPA by April 10, 

1995.

    (2) Subchronic toxicity--(i) Required testing. (A) An oral 90-day 

subchronic toxicity test shall be conducted with 1,3,5-trimethylbenzene 

in accordance with Sec.  798.2650 of this chapter except for the 

provisions in Sec.  798.2650 (e)(3), (e)(7)(i), and (e)(11)(v). The 

tests shall be performed using drinking water. However, if, due to poor 

stability or palatability, a drinking water test is not feasible for a 

given substance, that substance shall be administered either by oral 

gavage, in the diet, or in capsules.

    (B) For the purpose of this section, the following provisions also 

apply:

    (1) Satellite group (Rodent only). A satellite group of 20 animals 

(10 animals per sex) shall be treated with the high dose level for 90 

days and observed for reversibility, persistence, and delayed occurrence 

of toxic effects for a post-treatment period of appropriate length, 

normally not less than 28 days.

    (2) Histopathology. Histopathology of the lungs of all animals shall 

be performed. Special attention to examination of the lungs of rodents 

shall be made for evidence of infection since this provides a convenient 

assessment of the state of health of the animals.

    (ii) Reporting requirements. (A) The subchronic testing for 

chloroethane shall be completed and the final report submitted to EPA by 

June 27, 1995. The subchronic testing for 1,1-dichloroethane and 

1,1,2,2-tetrachlorethane shall be completed and the final report 

submitted to EPA by August 27, 1995. The subchronic testing for 1,3,5-

trimethylbenzene shall be



[[Page 275]]



completed and the final report submitted to EPA by April 10, 1995.

    (B) For each test, a progress report shall be submitted to EPA 

beginning 9 months after the date specified in paragraph (d)(1) of this 

section and at 6-month intervals thereafter until the final report is 

submitted to EPA.

    (d) Effective date. (1) This section is effective on December 27, 

1993, except for paragraphs (a)(1), (a)(2), (c)(1)(i)(A), (c)(1)(ii)(A), 

(c)(1)(ii)(B), (c)(2)(i)(A), and (c)(2)(ii)(A). The effective date for 

paragraphs (a)(2), (c)(1)(ii)(B), and (c)(2)(ii)(A) is September 29, 

1995. The effective date for paragraphs (a)(1), (c)(1)(i)(A), and 

(c)(2)(i)(A) is February 27, 1996. The effective date for paragraph 

(c)(1)(ii)(A) is June 30, 1997.

    (2) The guidelines and other test methods cited in this section are 

referenced as they exist on the effective date of the final rule.



[58 FR 59681, Nov. 10, 1993; 58 FR 1992, Jan. 13, 1994, as amended at 60 

FR 56956, Nov. 13, 1995; 61 FR 7223, Feb. 27, 1996; 62 FR 35105, June 

30, 1997]